SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (3280)11/4/2015 8:11:12 PM
From: Ian@SI  Read Replies (1) of 3661
 
I suspect that this one will be prone to tax loss selling as we approach year end.

I've traded it during the past year selling naked puts (in the money) as it approached lows, then covered calls as it approached highs (missed about $20 p/s of potential profit when Roche stepped in).

If it got a $15 or lower handle, I'd consider selling naked puts (ITM) again.

I suspect there's a cost reimbursement issue from the insurers. If I were a cancer patient looking for the best available tx, this seems like a no-brainer. Yet the sales haven't materialized. Something seems to be holding growth back even with Roche's help....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News